Full notification file
General informationNotification NumberB/NL/17/006Member State to which the notification was sentNetherlandsDate of acknowledgement from the Member State Competent Authority29/11/2017Title of the ProjectCTL019 – Autologous genetically modified T cells, intravenous infusion. Treatment of relapsed/refractory B cell malignanciesProposed period of release:01/11/2017 to 31/12/2047Name of the Institute(s) or Company(ies)Novartis Pharma AG, Postfach, 4002 Basel, Switzerland;
3. Is the same GMO release planned elsewhere in the Community?NoHas the same GMO been notified elsewhere by the same notifier?YesIf yes, notification number(s): B/DE/15/PEI/2484; B/DE/15/PEI2482; B/ES/15/08; B/ES/17/04; GMO characterizationGMO is a:Other: mammalIdentity of the GMO:CD4+ and CD8+ T cells transduced with a replication-deficient HIV-1 derived viral vector
to express a transmembrane chimeric (murine/human) antigen receptor (CAR).Information relating to the recipient or parental organisms from wich the GMO is derivedCommon Name | Genus | Species | Subspecies | Strain | Pathovar | Human | Homo | Sapiens | - | - | - |
|
European Commission administrative informationConsent given by the Member State Competent Authority:Not known